Earnings Feed
Start Free
Home/Filings/4/0001021771-24-000091
4//SEC Filing

Silva Francisco 4

Accession 0001021771-24-000091

CIK 0001505497other
View on SEC.govCompany Profile

Filed

Apr 9, 8:00 PM ET

Accepted

Apr 10, 5:16 PM ET

Size

19.5 KB

Accession

0001021771-24-000091

Insider Transaction Report

Form 4
Period: 2024-04-08
BioRestorative Therapies, Inc.BRTX
Silva Francisco
VP of Research and Development
Transactions
  • Purchase

    Common Stock

    2024-04-08$1.17/sh+1,232$1,441→ 149,159 total
  • Purchase

    Common Stock

    2024-04-08$1.13/sh+476$538→ 147,927 total
  • Purchase

    Common Stock

    2024-04-09$1.25/sh+6,600$8,250→ 155,759 total
Holdings

  • Stock Option

    Exercise: $3000.00Exp: 2028-10-29→ Common Stock (25 underlying)
    25

  • Stock Option

    Exercise: $5.08Exp: 2031-03-18→ Common Stock (293,479 underlying)
    293,479

  • Stock Option

    Exercise: $3000.00Exp: 2024-10-23→ Common Stock (9 underlying)
    9

  • Stock Option

    Exercise: $3000.00Exp: 2025-09-04→ Common Stock (6 underlying)
    6

  • Stock Option

    Exercise: $3000.00Exp: 2027-07-12→ Common Stock (20 underlying)
    20

  • Common Stock

    (indirect: By IRA)
    12,136

  • Stock Option

    Exercise: $3000.00Exp: 2026-06-10→ Common Stock (15 underlying)
    15

  • Stock Option

    Exercise: $5.08Exp: 2031-11-04→ Common Stock (42,059 underlying)
    42,059

  • Stock Option

    Exercise: $2.91Exp: 2033-02-17→ Common Stock (106,762 underlying)
    106,762

  • Stock Option

    Exercise: $1.45Exp: 2034-02-13→ Common Stock (394,737 underlying)
    394,737
Footnotes (4)
  • [F1]The option is currently exercisable.
  • [F2]The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
  • [F3]The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
  • [F4]The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.

Documents

1 file

Issuer

BioRestorative Therapies, Inc.

CIK 0001505497

→
Entity typeother

Related Parties

1
  • filerCIK 0001527241

Filing Metadata

Form type
4
Filed
Apr 9, 8:00 PM ET
Accepted
Apr 10, 5:16 PM ET
Size
19.5 KB
View on SEC.gov